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Genomic loss of the patient-specific HLA has been
described in previous single-center studies as a frequent
mechanism of leukemia immune evasion and relapse. Here
we present the first global collaborative study to investigate
its incidence across transplant platforms.
Twenty-seven transplant centers from across the globe
formed the HLALOSS consortium and collected a total of
634 cases of relapse after allogeneic HSCT from HLA-
haploidentical relatives (29.3%), HLA-mismatched unrelated
donors (MMUD, 25.9%), 10/10-matched unrelated donors
(MUD, 35.8%), or unrelated cord blood units (UCB, 9.0%).
Cases were analyzed using conventional HLA typing, the
recently developed HLA-KMR assay (Ahci and Toffalori,
Blood, 2017) or a novel Next-Generation Sequencing
(NGS) method developed to cover all possible HLA-A, -B,
-C, -DRB1, -DQB1 and -DPB1 alleles and to analyze multi-
ple samples in a single run. To date, we analyzed
222 relapses, 127 of which using the newly developed
HLA-NGS platform. This method resulted highly robust,
reliable and sensitive: allowing with a minimum read-depth
of 1000x the detection of up to 0.5% of target DNA. False
positive reads for patient-specific HLA alleles were detected
in 34/73 donor samples, but they were as low as 0.5% on
average, and always restricted to one single exon of one or
two loci. Ten relapses tested in parallel via HLA-NGS and
HLA-KMR showed remarkable concordance between the
two methods (R2=0.86, p<0.0001). In the total 222 cases
analyzed to date, we documented 35 HLA loss relapses,
27 of which after haploidentical HSCT (26.0% of relapses
in this setting), 7 after MMUD HSCT (11.5%), 1 after
10/10 MUD HSCT (2%) and none after UCB HSCT. The
present data, obtained from the largest collaborative study
on the immunobiology of relapse to date, confirm the clini-
cal relevance of HLA loss as a major mechanism of recur-
rence, including after HSCT from unrelated donors.
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Preserving the semi-allogeneic fetus during pregnancy relies
on finely tuned maternal immune adaptations. To better
understand the dynamics of maternal immune cell types at
the maternal-fetal interface throughout gestation, a system-
wide and in-depth approach was undertaken. Mass cytome-
try was applied to determine the composition of the mater-
nal myeloid and lymphoid immune compartments from the
beginning of pregnancy until parturition. Immune cell het-
erogeneity within leukocytes isolated from first trimester (6-
13 wks) and term pregnancy decidua, as well as peripheral
blood from the mother at time of delivery was visualized by
high dimensional single-cell t-SNE and HSNE-based analy-
sis tools starting with an overview level of all major
immune cell lineages and zooming into distinct immune cell
subsets. In a data-driven and unbiased manner, utilizing
39 immune cell markers simultaneously, we identified the
presence of multiple innate lymphocyte subsets in the first
trimester, decreasing towards the end of pregnancy, con-
trasting the dynamics of diversifying T cell subsets through-
out gestation. Furthermore, several immune cell types
residing in the decidua clustered completely separate from
immune cell types in the peripheral blood, revealing a
unique immune cell composition at the maternal-fetal inter-
face. Separate clustering was also observed between differ-
ent gestational ages. This study provides insight into how
the local maternal immune landscape changes over the
course of pregnancy and identified a specific immune cell
subset composition in both the innate and adaptive immune
compartment. Understanding the organization of immunity
at the maternal-fetal interface and the changes that occur
from beginning until the end of gestation leads the way in
recognizing dysregulated immune mechanisms that drive
pregnancy complications.
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We report transmission of acute myeloid leukemia (AML)
from a 79-year old cadaveric female donor, deceased
because of brain hemorrhage, to two kidney and one liver
recipients, transplanted in October 2011. According to
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Donor Safety Guidelines released by Italian Competent
Authority, donor risk was standard. No clinical, imaging or
laboratory records of the donor led to suspect AML. After
the alert from nephrologists suggesting the possible trans-
mission of donor-related AML in the 2 kidney recipients
(R1, a male patient of 57 at the time of transplantation,
diagnosed with AML in May 2013 and R2, a female patient
of 50 at the time of transplantation, diagnosed with AML in
June 2013), it was ascertained that also the liver recipient
(R3) had died from AML complications in November 2012.
R1 received treatment for leukemia, but died of complica-
tions in October 2012, while R2 went into complete remis-
sion until February 2017 when she relapsed. She then
received an allogenic bone marrow transplantation but died
of treatment-induced complications in December 2017. Ret-
rospective analysis of mutations in the nucleophosmin
(NPM1) and Fms-like tyrosine kinase 3 (FLIT3) genes was
performed using the buffy coat from the donor and samples
from R1 and R2 before and after kidney transplantation.
NPM1 mutation was present in 17% of donor, in 49% of R1
and in 24% of R2 blood samples, respectively. The FLIT3
mutation was detected exclusively in R1 (44%), suggesting
a distinct clonal evolution. Microsatellite analysis confirmed
donor chimerism in circulating cells from R1 and R2 (83%
and 29% donor DNA, respectively). Whole exome DNA
sequencing was performed on the donor DNA, and on R1
and R2, prior and after kidney transplantation. Allele fre-
quency distributions confirmed the different degrees of chi-
merism after transplant and enabled the detection of
additional mutations. Exome sequencing data were also
used to analyze genome wide copy number variation, which
suggested copy number loss of the HLA-A region, in both
R1 and R2, potentially providing a molecular mechanism
for tumor escape. This is the first report of AML transmis-
sion following solid organ transplantation and NGS analysis
highlights molecular mechanisms explaining evolution of
the tumor and escape from immune response.
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The effects of aging on the immune system are manifest at
multiple levels that include reduced production of B and T
cells in bone marrow and thymus, and diminished function
of mature lymphocytes in secondary lymphoid tissues. As a
result, elderly individuals do not respond to immune chal-
lenge as robustly as the young. Not only adaptive immunity,
but also the innate immune response also declines with age.
There are changes in innate cell numbers, with skewing of
hematopoiesis towards the myeloid lineages. Ageing macro-
phages and dendritic cells display reduced phagocytic func-
tion and HLA class II expression. We analyzed peripheral
blood leucocytes in 78 healthy unrelated donors and in
12 related members of several three generation families.
The genotyping of HLA-DRB1, HLA-DQB1 and HLA-
DQA1 was performed using PCR with sequence specific
primers. The Real-Time PCR was applied to quantify differ-
ences in HLA-DQA1 and HLA-DQB1 gene expression.
The Chromatin ImmunoPrecipitation (ChIP) assay was used
to isolate chromatin fragments containing acetylated histone
protein H3 associated with DQA and DQB promoter
regions. We detected the activation marker (acetyl-H3) and
the inhibition marker (trimethyl-H3K9). At both levels
(mRNA transcription and histone modification), senescence
of immune system has been characterized by the decreased
gene expression of HLA-DQ alleles. The highest expression
of DQ beta gene was detected in adulthood, the lowest one
in seniors (p=0.02). Similar results were obtained also for
DQ alpha gene. Moreover, the histone acetylation and meth-
ylation have shown the age specific level of histone modifi-
cation of each allele. Besides non-relative individuals we
studied also three-generation family, where we proved that
one allele, transmitted from generation to generation, is dif-
ferentially epigenetically modified in dependence on age of
its carrier.
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The remarkable polymorphism of the human leukocyte anti-
gen (HLA) genes is usually seen as the result of a selective
advantage due to the essential function of the HLA mole-
cules in the presentation of pathogen-derived peptides to the
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